- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02398227
Treatment of PTSD in Residents of Battered Women's Shelters (HOPE)
Study Overview
Detailed Description
Research suggests that approximately 1 in 4 women report a history of intimate partner violence (IPV), and IPV is associated with severe psychological problems, especially PTSD. Battered women's shelters annually provide emergency shelter to approximately 300,000 women and children. A prime time to intervene with IPV victims might be when they enter shelter and have already initiated a change in their life. Standard shelter care typically includes case management to help women access resources that can assist them in establishing long-term safety for themselves and their children. However, PTSD symptoms may compromise victims' ability to effectively use integral community resources, as well as their ability to appropriately react to threat relevant information, interfering with their ability to establish safety for themselves and their children. As such, research has found PTSD to be associated with re-abuse in victims of IPV.
Despite the significant morbidity associated with IPV-related PTSD, our treatment, Helping to Overcome PTSD through Empowerment (HOPE), is the only extant treatment to date that has been developed to specifically target IPV-related PTSD in residents of battered women's shelters. Cognitive-behavioral treatments (CBT) for PTSD have been shown to be effective with multiple populations but do not address the unique needs of recent IPV victims. HOPE, a shelter-based, individual, brief CBT treatment for PTSD in victims of IPV, addresses IPV victims' current needs of safety, self-care, protection, and empowerment, as well as the exchange of information on PTSD symptoms and how these symptoms interfere with the use of shelter and community resources and their ability to establish safety. HOPE was specifically designed to serve as an evidence-based model program that could be implemented in a wide-range of shelter programs across the United States. The current proposal builds on the foundation of our NIMH-funded treatment development study (R34MH080786). Pilot work with HOPE supports the initial acceptability and feasibility of this new treatment. IPV victims who received a significant dose of HOPE were 12 times less likely than women received only standard shelter services to report being re-abused after leaving shelter. Further, women who received HOPE displayed fewer PTSD arousal and avoidance symptoms of PTSD, less depression, and greater social support and empowerment relative to women who did not receive HOPE. The overall aim of this project is to test the efficacy of HOPE relative to supportive therapy (i.e., Present Centered Therapy, PCT) in a sample of 186 female residents of battered women's shelters with IPV-related PTSD. In an effort to facilitate future dissemination of HOPE, sessions will be delivered by community therapists and the study will be conducted in a range of shelter systems. Furthermore, the current proposal, unlike the pilot study, will compare HOPE to an attention matched control condition, have a longer follow-up period, will assess the impact of HOPE on child abuse potential, and will incorporate objective measures of stress responding (e.g., attentional biases and physiological reactivity to trauma cues), explore mediators and moderators of treatment, and evaluate the cost effectiveness of HOPE.
The Specific Aim of this proposal is to conduct a randomized controlled trial comparing HOPE to PCT in residents of battered women shelters with IPV-related PTSD. The study will test the following hypotheses:
Primary Hypotheses: HOPE will be significantly more efficacious than PCT in reducing participants' IPV-related PTSD symptoms and severity of re-abuse over a one-year follow-up.
Secondary Hypotheses: Associated Symptoms, Psychosocial Functioning, and Cost:
- HOPE will be significantly more efficacious than PCT in decreasing participants' depressive symptoms and child abuse potential; in increasing participants' degree of empowerment, quality of life, degree and quality of social support, effective use of resources, and traumatic cognitions over a one-year follow-up.
- Shelter residents who receive HOPE will display reduced biases in attention to threat-related information and normalization of physiological reactivity to trauma cues, relative to women who receive PCT over a one-year follow-up.
- We also plan to evaluate the cost-effectiveness of HOPE measured by cost per quality adjusted life year saved (QULY).
We will also explore the following hypotheses regarding potential mediators and moderators of HOPE:
- The effect HOPE has on PTSD over the one-year follow-up will be mediated by participants' degree of empowerment, effective use of resources, and traumatic cognitions at post-treatment.
- HOPE participants' PTSD symptoms post-treatment will mediate participants' severity of re-abuse over the one-year follow-up period.
- We also plan to explore whether the following baseline variables are moderators of treatment response: minority status, IPV and PTSD severity, attentional biases to threat related information, and physiological reactivity to trauma cues.
HOPE, a novel treatment for battered women with IPV-related PTSD, has the potential to provide a national model of care for a vulnerable, underserved, and understudied population.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Akron, Ohio, United States, 44325
- University of Akron
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- must be resident in one of the 6 participating shelters,
- IPV in month prior to shelter,
- PTSD
Exclusion Criteria:
- substance dependence in last 3 months,
- change in meds in last month,
- Bipolar d/o,
- psychosis,
- active suicidality
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HOPE
Cognitive Behavioral Treatment Program for PTSD
|
Cognitive Behavioral Treatment for PTSD in Battered Women
|
Active Comparator: PCT
Present Centered Therapy for PTSD
|
Present Centered Therapy for PTSD
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinician Administered PTSD Scale (CAPS)
Time Frame: baseline, post-shelter, post-treatment, 6 months post-treatment, 1 year post-treatment
|
Clinical Interview assessing symptoms of Posttraumatic Stress Disorder (PTSD) scores can range from 0 to 136 with higher scores reflecting greater PTSD severity Adjusted means with baseline scores as a covariate are reported
|
baseline, post-shelter, post-treatment, 6 months post-treatment, 1 year post-treatment
|
Severity of Violence Against Women Scale (SVAWS)
Time Frame: baseline, post-shelter, post-treatment, 6-month post-treatment, 1 year post-treatment
|
Severity of Violence Against Women Scale total score.
Scores can range from 0 to 138 with higher scores reflecting greater degree of violence/abuse.Adjusted means with baseline scores as a covariate are reported
|
baseline, post-shelter, post-treatment, 6-month post-treatment, 1 year post-treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Dawn M Johnson, Ph.D., The University of Akron
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 1R01MH095767 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PTSD
-
University of PittsburghCompletedPTSD | Non PTSDUnited States
-
University of Alabama, TuscaloosaRecruiting
-
Research Foundation for Mental Hygiene, Inc.University of California, San Diego; Northwell Health; Columbia University; Icahn... and other collaboratorsRecruiting
-
University of Wisconsin, MadisonWisconsin Partnership ProgramRecruiting
-
Rush University Medical CenterRecruiting
-
New York State Psychiatric InstituteCompleted
-
University of WashingtonPatient-Centered Outcomes Research Institute; Boston University; Washington State... and other collaboratorsActive, not recruiting
-
VA Salt Lake City Health Care SystemUtah State UniversityActive, not recruiting
-
VA Office of Research and DevelopmentCompleted
Clinical Trials on HOPE
-
Pepperdine UniversityUniversity of California, Los Angeles; University of California, IrvineCompleted
-
University Hospital, AngersUnknown
-
The University of AkronNational Institute of Mental Health (NIMH); Butler Hospital; Summa Health SystemCompletedPost-Traumatic Stress Disorder | Battered WomenUnited States
-
University of California, IrvineActive, not recruitingCOVID-19 VaccinationUnited States
-
Medical College of WisconsinEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingParent-Child Relations | Premature InfantsUnited States
-
University of ManitobaHealth Sciences Centre Foundation, ManitobaActive, not recruitingSuicidal Ideation | Suicide, Attempted | SuicideCanada
-
Memphis VA Medical CenterVirginia Commonwealth University; University of TennesseeActive, not recruitingTBI (Traumatic Brain Injury) | Dementia, Mixed | Dementia of Alzheimer TypeUnited States
-
Göteborg UniversityCompleted
-
University of FloridaAmerican Pain SocietyCompletedTemporomandibular Joint DisorderUnited States